Marko Mychaskiw, PhD

Drug–Drug Interactions With Vesicular Monoamine Transporter 2 Inhibitors: Population Estimate of Patients With Tardive Dyskinesia at Risk in Real-World Clinical Practice

Valbenazine and deutetrabenazine product labeling both recommend dose adjustment for and/or avoidance of certain concomitant medications because of potential for drug–drug interactions (D...

Marko Mychaskiw , PhD;

10/26/2023

Real-World Antipsychotic and Vesicular Monoamine Transporter Type 2 Inhibitor Treatment Patterns in Patients Newly Diagnosed With Tardive Dyskinesia

Antipsychotic (AP) and vesicular monoamine transporter type 2 inhibitor (VMAT2i) treatment patterns post-tardive dyskinesia (TD) diagnosis are unclear. Deutetrabenazine (DTBZ) is a VMAT2i...

Marko Mychaskiw , PhD;

10/26/2023

Real-World Antipsychotic Treatment Modification With and Without Deutetrabenazine in Patients Newly Diagnosed With Tardive Dyskinesia

Tardive dyskinesia (TD) management includes antipsychotic (AP) dose modification/discontinuation, often leaving underlying psychiatric conditions undertreated. Deutetrabenazine (DTBZ) is ...

Marko Mychaskiw , PhD;

10/26/2023

Educational Needs of Caregivers of Patients With Schizophrenia: Results of a National Survey Study

BACKGROUND: Caregivers of patients with schizophrenia are an often-overlooked target for education, but may be a key resource to promote therapeutic adherence and patient education. OBJE...

Emily Belcher , BS;

Sylvie Stacy , MD, MPH;

Mark Suett , MBChB, MRCP, DPM;

Marko Mychaskiw , PhD;

Gregory Salinas , PhD;

Leslie Citrome , MD;

10/08/2020

Influence of Cultural Differences and Genetic Polymorphisms on Schizophrenia Management: An Exploratory Targeted Literature Review

Abstract: Objective: Cultural differences impact schizophrenia management across countries and may complicate the evaluation of new therapeutics. Genetic polymorphisms are associated with...

Marko Mychaskiw , PhD;

Kelsey Hogan ;

01/19/2023

Clinical Dilemmas in Schizophrenia Treatment and the Potential Place in Therapy of Long-acting Antipsychotic Agents

Abstract: Introduction: Treatment nonadherence in schizophrenia is a continuing challenge, but can be improved with use of long-acting injectable antipsychotic agents (LAIs). Although wel...

Marko Mychaskiw , PhD;

Kelsey Hogan ;

01/19/2023

Introducing S.C.O.P.E.™: Schizophrenia Clinical Outcome Scenarios and Patient-Provider Engagement—An Interactive Digital Platform to Educate on Schizophrenia Care

Abstract: Introduction: Healthcare professionals (HCPs) face unique challenges when managing patients with schizophrenia. Educational initiatives targeting the most common dilemmas encoun...

Marko Mychaskiw , PhD;

Kelsey Hogan ;

01/19/2023

Dispelling Myths and Misconceptions Surrounding the Use of Long-acting Injectable Antipsychotic Agents for Treatment of Schizophrenia

Abstract: Introduction: Schizophrenia affects over 3 million people in the United States. Despite data supporting the use of long-acting injectable antipsychotic agents (LAIs), myths and ...

Marko Mychaskiw , PhD;

Kelsey Hogan ;

01/19/2023